Evidence map›Paper›PMID 39768459›Full record

ReviewJournal of clinical medicine2024

Advancements in Minimally Invasive Techniques and Biomarkers for the Early Detection of Endometrial Cancer: A Comprehensive Review of Novel Diagnostic Approaches and Clinical Implications.

Aleksandra Asaturova, Andrew Zaretsky, Aleksandra Rogozhina, Anna Tregubova, Alina Badlaeva

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07264660 (Diagnostic Value of Transcervical True-Cut Biopsy in Uterine Masses), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07264660 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Diagnostic Value of Transcervical True-Cut Biopsy in Uterine Masses

TypeobservationalSponsorAssiut UniversityRan2025 to 2027Enrolled42ConditionsUterine TumorArmsTranscervical True-Cut Biopsy
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aleksandra AsaturovaFederal State Budgetary Institution "National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov", Ministry of Healthcare of the Russian Federation, Oparina Street, Bld. 4, 117997 Moscow, Russia.ORCID 0000-0001-8739-5209
Andrew ZaretskyFederal State Budgetary Institution "National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov", Ministry of Healthcare of the Russian Federation, Oparina Street, Bld. 4, 117997 Moscow, Russia.ORCID 0000-0002-7778-6617
Aleksandra RogozhinaFederal State Budgetary Institution "National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov", Ministry of Healthcare of the Russian Federation, Oparina Street, Bld. 4, 117997 Moscow, Russia.
Anna TregubovaFederal State Budgetary Institution "National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov", Ministry of Healthcare of the Russian Federation, Oparina Street, Bld. 4, 117997 Moscow, Russia.ORCID 0000-0003-4601-1330
Alina BadlaevaFederal State Budgetary Institution "National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov", Ministry of Healthcare of the Russian Federation, Oparina Street, Bld. 4, 117997 Moscow, Russia.ORCID 0000-0001-5223-9767

Funding

Government assignment 124040300006-2, "Development of a diagnostic assay for early signs of cervical and en-dometrial cancer using epigenetic analysis of DNA from cervical smears".
6 · The paper itself

Abstract

This review evaluates the advances in the early detection and diagnosis of endometrial cancer (EC), emphasizing the growing importance of minimally invasive techniques and novel biomarkers. Current diagnostic protocols for EC rely heavily on invasive procedures such as transvaginal ultrasound (TVU), hysteroscopy, and endometrial biopsy, which, although effective, can be overly burdensome for patients and inefficient for asymptomatic or low-risk populations. As there is no consensus on EC screening in high-risk or general populations, recent studies have explored alternative methods using biofluids and genomic biomarkers to improve sensitivity and specificity and facilitate access for patients. This review summarizes findings on DNA methylation markers, circulating tumor-derived nucleic acids, and the potential of liquid biopsy approaches for the early detection of EC. These innovations may not only streamline screening but also reduce the need for invasive procedures. This review highlights the potential of these biomarkers to be integrated seamlessly into the existing cervical cancer screening programs, which could transform screening methods for endometrial cancer and support the development of personalized, less invasive diagnostic procedures.

Indexed as

cancer screeningcervical cytologycervicovaginal cytologyDNA methylationearly detectionendometrial cancerepigeneticsgenetic biomarkersliquid biopsynon-invasive biomarkers

Identifiers

PMID39768459
PMCPMC11728107

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.